Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • Monday
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingGlobeNewsWire • 10/24/26
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal MelanomaSeeking Alpha • 08/25/26
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026GlobeNewsWire • 07/17/26
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual MeetingGlobeNewsWire • 06/01/26
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung CancerGlobeNewsWire • 05/31/26
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual MeetingGlobeNewsWire • 05/30/26
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual MeetingGlobeNewsWire • 04/21/26
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 CongressGlobeNewsWire • 12/11/25
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development StepsGlobeNewsWire • 11/12/25
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential SymposiumGlobeNewsWire • 10/20/25